Age-related change in brain metabolite abnormalities in autism: a meta-analysis of proton magnetic resonance spectroscopy studies by Aoki, Y et al.
Age-related change in brain metabolite abnormalities
in autism: a meta-analysis of proton magnetic
resonance spectroscopy studies
Y Aoki
1, K Kasai
1 and H Yamasue
1,2
Abnormal trajectory of brain development has been suggested by previous structural magnetic resonance imaging and head
circumference ﬁndings in autism spectrum disorders (ASDs); however, the neurochemical backgrounds remain unclear. To
elucidate neurochemical processes underlying aberrant brain growth in ASD, we conducted a comprehensive literature search
and a meta-analysis of
1H-magnetic resonance spectroscopy (
1H-MRS) studies in ASD. From the 22 articles identiﬁed as
satisfying the criteria, means and s.d. of measure of N-acetylaspartate (NAA), creatine, choline-containing compounds, myo-
Inositol and glutamateþglutamine in frontal, temporal, parietal, amygdala-hippocampus complex, thalamus and cerebellum
were extracted. Random effect model analyses showed signiﬁcantly lower NAA levels in all the examined brain regions but
cerebelluminASDchildrencomparedwithtypicallydevelopedchildren(n¼1295atthemaximuminfrontal,Po0.05Bonferroni-
corrected), although there was no signiﬁcant difference in metabolite levels in adulthood. Meta-regression analysis further
revealed that the effect size of lower frontal NAA levels linearly declined with older mean age in ASD (n¼844, Po0.05
Bonferroni-corrected). The signiﬁcance of all frontal NAA ﬁndings was preserved after considering between-study
heterogeneities (Po0.05 Bonferroni-corrected). This ﬁrst meta-analysis of
1H-MRS studies in ASD demonstrated robust
developmentalchangesinthedegreeofabnormalityinNAAlevels,especiallyinfrontallobesofASD.Previouslyreportedlarger-
than-normal brain size in ASD children and the coincident lower-than-normal NAA levels suggest that early transient brain
expansion in ASD is mainly caused by an increase in non-neuron tissues, such as glial cell proliferation.
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Introduction
Autism spectrum disorder (ASD) is a representative neuro-
developmental disorder that is behaviorally deﬁned by deﬁcits
in social reciprocity, impaired verbal communication, and
restrictive and repetitive behavior.
1,2 In the background of
such atypical behavioral development, previous studies have
suggested the existence of atypical brain development in
ASD that overall brain size was slightly reduced at birth,
dramatically increased within the ﬁrst year of life, but then
gradually plateaued into adulthood.
3–5 However, brain size
studies cannot provide tissue neurochemical information.
Although post-mortem studies demonstrated cytoarchitec-
tonic abnormalities, aberrant minicolumnar organizations
and microglial activations in brains of autistic individuals,
6
post-mortem studies lack information about the trajectory of
brain development. Therefore, the neural mechanisms
explaining the aberrant trajectory of brain growth in ASD are
yet to be elucidated, although several hypotheses such as
excess neuron number have been proposed.
6,7
1H-magnetic resonance spectroscopy (
1H-MRS) is a non-
invasive neuroimaging technique that estimates speciﬁc
chemical metabolite measures in vivo.
8 Previous studies
have used
1H-MRS to quantify glutamine/glutamate (referred
to collectively as ‘Glx’); N-acetylaspartate (NAA), a marker of
neuronal density and activity;
9 choline-containing compounds
(Cho), a measure primarily reﬂecting the constituents of
cell membranes;
10 creatine and phosphocreatine (Cre), a
measure of cellular energy metabolism;
10 and myo-Inositol
(mI), a major osmolite, precursor for phosphoinositides
involved in the second messenger system.
11 Previous
1H-MRS ﬁndings have yielded some inconsistency such as
decreased
12–14 or no difference or increased NAA measure in
ASD people compared with typically developed (TD) indivi-
duals.
15–18 The statistical power of each single previous
1H-MRS study is relatively small, and previous studies have
not corrected for multiple comparisons. As brain structural
studies show an aberrant trajectory of neurodevelopment, it
was reasonable to predict that the degree of neurochemical
abnormalities indexed by
1H-MRS may also change accord-
ing to developmental stages in ASD. However, to date
only one longitudinal
1H-MRS study focusing on lactate level
has been reported.
19 Therefore, performing a meta-analysis
is one possible solution to realize sufﬁcient statistical
power for making conclusion about the neurochemical
abnormality of autistic brain and is currently the only way to
examine age-related change of
1H-MRS abnormality of
autistic brain.
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www.nature.com/tpTo our knowledge, neither a systematic review nor a meta-
analysis of
1H-MRS studies in people with ASD has been
reported previously. The current systematic review and meta-
analysis were designed to test the hypothesis that the degree
of abnormalities in metabolite levels measured with
1H-MRS
would change from childhood to adulthood. Concretely, in case
that autistic early brain expansion is mainly caused by increase
in neuronal tissue, transient increase in NAA level would be
foundduringchildhoodbutitwouldnotbefoundinadulthood.On
the other hand, if increase in non-neuronal tissue mainly con-
tributes to early brain expansion, NAA level would be remained
at normal or even on a decline in childhood but in adulthood.
Materials and methods
Data sources.
1H-MRS studies that examined metabolite
measures in the brains of individuals with ASD and TD
control subjects were obtained through the computerized
databases MEDLINE, PsycINFO, EMBASE and Web of
Science. The search terms used in the systematic screening
were autism, autistic, ASD, Asperger’s, developmental disorder,
pervasive developmental disorder (PDD) and mental deve-
lopment, w h i c hw e r ea l s oc o m b i n e dw i t hmagnetic resonance
spectroscopy and MRS. Titles and abstracts of studies were
examined to check whether or not they could be included.
Reference lists of included articles were also examined to search
additional studies to be included.
Selection of study. Studies were included if (1) they
were brain
1H-MRS studies published between 1980 and
December 2010, (2) they examined people with ASD
compared with a TD control group and (3) they reported
sufﬁcient data to obtain signiﬁcant effect sizes; means, s.d.
and numbers of participants. The literature search was
performed without language restriction. If they did not report
sufﬁcient data, we emailed the corresponding and then the
last author to obtain them. In cases where neither of them
responded, we excluded the study. Two reviewers (YA and
HY) performed study screenings independently.
Data extraction. To perform the meta-analyses, we deﬁned
a standardized mean difference as the effect size statistic
Cohen’s d, which is calculated as the difference between
the mean of the experiment group and the mean of the
comparison group divided by the pooled s.d. In the current
meta-analyses, mean measure of NAA, Cre, Cho, mI and Glx
in autistic individuals was subtracted from those in TD groups
in each volume of interest (VOI) respectively, and divided by
the pooled s.d. of both. Data were separated by the mean
age of participants to examine the hypothesis the degree of
metabolite measure abnormality would change from
childhood to adulthood. When the mean age of participants
was 420, the study was included in the meta-analysis in
adulthood.
15,18,20,21 In a study reporting the age range as
from 3 to 5 years with no description of the mean age of
participants, we considered the participants to have a mean
age of 4 years.
22 In cases of studies reporting more than two
measures of metabolites, we determined the priority for
extraction as absolute measure then ratio to Cre. Two
reviewers (YA and HY) performed all the data extraction and
computation of effect size independently to minimize errors.
Meta-analysis of Observational Studies in Epidemiology
guidelines
23 were followed in the study.
Identiﬁcation of brain regions. Our hypothesis focused
on the developmental aspect of autistic brain pathology,
we classiﬁed the sub-regions into frontal, amygdala-hippo-
campus complex (AHC), temporal, parietal, cerebellum and
thalamus, in line with the similarity of developmental
background within each sub-region.
24 In the case of a
study reporting measures from more than one sub-region in
one area (for example, anterior cingulate cortex and
dorsolateral prefrontal cortex), these were assigned to the
appropriate meta-analysis sub-group (that is, frontal lobe) as
two (or more) independent data sets regardless of tissue type,
such as gray matter, white matter or both. VOIs in the medial
temporal lobe that included the hippocampus or amygdala
region were included into AHC sub-group.
13,22,25 VOIs in the
intraparietal sulcus
20 and temporoparietal junction
20 were
assigned to the parietal lobe, while that in the insula
14 was
assigned to the temporal lobe. To ensure the meta-analysis
was sufﬁciently powered, brain region measures were
included if there were two or more studies reporting more
than three VOIs in total. VOIs in TD control subjects who were
compared with more than two ASD groups were identiﬁed
25,26
and divided into the appropriate number of comparison sub-
groups to avoid duplicate counting.
Meta-analysis. All meta-analyses were performed using
Review Manager ((RevMan) [Computer program], Version 5.1,
Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2011) from the Cochrane collaboration. A
random effect model was adapted for the current meta-
analysis to control potential heterogeneity such as variation in
location of VOI, implementation of tissue segmentation within
VOIs, single- vs multi-voxel spectroscopy, echo time, volume of
VOI and types of metabolites measure. Cohen’s d was
calculated and used as effect sizes. As the differences in
metabolite levels in ASD compared with TD subjects were
predicted to differ between childhood and adulthood, the com-
parison was examined separately in childhood and adulthood.
We employed conservative deﬁnitions of signiﬁcance level
determined using Bonferroni corrections, with Po0.0022 in
childhood (¼0.05/23 included metabolites in six regions) and
Po0.0033 in adulthood (¼0.05/15 included metabolites in
four regions; Table 2).
Sensitivity analyses. The robustness of signiﬁcant ﬁndings
from meta-analysis was further tested by sensitivity analysis
in speciﬁed sub-groups excluding studies with potential
confounds. These potential confounds included comorbid
epilepsy, medication, presence of mental retardation, ﬁeld
strength of MR scanner, types of MRS measures, segmen-
tation within VOIs and diagnostic tools. The signiﬁcance
level was deﬁned as Po0.0014 (¼0.05/35 comparisons
(7 potential confounds 5 regions)).
Meta-regression. To test the hypothesis that neurochemical
abnormalities would change with age, we performed
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sample to examine the relation between participants’ mean
age and Cohen’s d for the NAA levels in the frontal lobe,
parietal lobe and AHC in which the meta-analysis revealed
signiﬁcant differences between ASD and TD individuals in
childhood or adulthood, with sufﬁcient sample sizes to test
meta-regression (n410).
27 The regression was examined
using SPSS 18.0 (SPSS, Chicago, IL, USA). The level of
statistical signiﬁcance was deﬁned, by applying the
Bonferroni correction, as Po0.012 (¼0.05/4 areas).
The current meta-analyses included studies with consider-
able heterogeneities; such as presence of mental retar-
dation, medication, types of MRS measures, employment of
segmentation within the VOI, volume of VOI and comorbid
epilepsy (for example, absolute measure or ratio to Cre).
To investigate the inﬂuence of these potential modiﬁers, we
performed meta-regression analyses for the metabolite
measures in which the current meta-analyses showed
signiﬁcant difference between subjects with ASD and TD.
The meta-regressions were examined in the childhood and
adulthoodcombinedsampletoexamineinasufﬁcientnumber
of data sets.
27 The signiﬁcance level was set at Po0.05 to
strictly assess the effect of heterogeneity.
Assessing between-study heterogeneity. The Cochran Q
and I
2 statistics were employed to examine between-study
heterogeneity. The signiﬁcance level was deﬁned as Po0.10
to conclude the studies were heterogeneous.
28
Publication bias. Publication bias was assessed qualita-
tively by visual inspection of funnel plots and quantitatively
by linear regression analysis for each group and each brain
region. Based on previous literature,
27 this calculation was
tested with data sets of at least 10.
Data synthesis. Twenty-three demographic, clinical and
methodological variants, including the number of partici-
pants, number of male participants, mean age, range of
age, intelligence quotient range, diagnostic criteria or tools,
pharmacological status, presence of comorbid epilepsy,
sequence for MRS acquisition, utilization of segmentation
within VOIs, strength of magnetic ﬁeld (Tesla), echo time
(TE), repetition time (TR), types of MRS measurements
(absolute measure or ratio to Cre), type of metabolites
reported, location of VOI, size of VOI, and main results of the
study were extracted, as shown in Table 1. Total number of
participants, studies and VOIs, and mean difference, 95%
conﬁdence interval, P-value, I
2 score and signiﬁcance of
linear regression analysis of symmetric property of funnel
plots calculated from each meta-analysis are shown in Table 2.
Results
Study selection. The literature search described above
yielded 244 articles, of which 47 studies were identiﬁed
as potential candidates for the meta-analysis. Nine articles
were excluded because lack of the original data. Ten
were excluded because they did not recruit ASD individual.
Two were excluded because of not utilizing
1H-MRS. Two were
excluded because not reporting new data. Thus, 24 studies
were included into the database.
12–18,20–22,25,26,28,29,31–39 From
the database, one study was excluded from the meta-analysis
because they did not report raw data regarding the metabolite
measure
28 and one study was excluded because it did not
p r o v i d es u f ﬁ c i e n td a t at oc a l c u l a t et h es t a n d a r d i z e dm e a n
difference
36 (Figure 1).
Database. Studies included in the meta-analysis involved
569 participants with ASD and 415 TD control subjects.
Table 1 summarizes variables recorded in the syste-
matic review. Among these studies, 17 examined
children,
12–14,16,22,25,26,28,29,31–36,39 including 447 with
ASD and 285 with TD, while eight studies examined
adults,
16–18,20,21,37,38 including 122 with ASD and 130 with
TD. Fourteen studies recruited participants with mean
intelligence quotient 70 or more,
12,14–17,20,21,25,26,37–39
whereas eight articles did not mention the precise mean
or range of intelligence quotient.
13,22,28,29,31–36 Three child
studies
22,33 included 19 ASD children with comorbid
epilepsy, while only one adult study included one ASD
subjects with epilepsy.
37 Five child studies
13,16,25,26,29 and
four adult studies
16,17,20,21 included individuals with drug-
naı ¨ve or no medication only, although medication status
was unclear in some studies.
22,28,31–35,38,39 Diagnosis
of ASD was determined based on DSM-IV (15
studies),
12,14,18,20,22,25,26,28,29,31,32,36–38 DSM-III (one study),
33
or ICD-10 (ﬁve studies)
15–17,34,35 criteria. Among the studies
employing DSM-IV or DSM-III, 10 used Autism Diagnostic
Interview-Revised (ADI-R)
12–15,17,20,37–39 or ADI,
16 10 utilized
Autism Diagnostic Observation Schedule (ADOS)
14,16,21,37–39 or
Autism Diagnostic Observation Schedule-Generic
(ADOS-G),
12,13,20 a n dn i n ee m p l o y e db o t h .
12–14,16,20,21,37–39
For image acquisition, 12 studies utilized point-resolved selec-
tive spectroscopy,
15–18,20,21,26,29,31,34,36,37 while six employed
1H-stimulated echo acquisition mode sequence.
22,28,32,33,35,39
Four studies
12,20,22,32 used 3-tesla MRI scanners, while 20
studies
13–18,21,22,25,26,28,29,31,33–39 utilized 1.5-tesla scanners.
Twelve child studies
12–14,16,22,28,31,32,34–36,39 and seven adult
studies
15–17,20,21,37,38 employed MRS measures with estimation
of absolute measure. Seven child studies
12–14,16,25,32,39 and ﬁve
adult studies
15–17,21,38 utilized tissue segmentation within VOIs.
Meta-analysis for metabolite measures in childhood and
adulthood. In childhood, individuals with ASD showed
signiﬁcantly reduced NAA levels compared with TD controls
in all the brain regions but cerebellum included in the
meta-analysis (Po0.05, Bonferroni-corrected; Figure 2). In
contrast, no signiﬁcant difference was found in other
metabolite concentrations between children with ASD and
TD controls. Although several metabolites showed differen-
ces in levels between children with ASD and TD at the trend
level signiﬁcance (NAA in the cerebellum: P¼0.008; mI in
the frontal areas: P¼0.008; Cre in the frontal areas:
P¼0.01, in AHC: P¼0.009; in the thalamus: P¼0.04;
Cho in the thalamus: P¼0.03), these signiﬁcant effects
disappeared after the Bonferroni correction for multiple
comparisons was applied (Table 2).
In contrast to childhood, no metabolites showed a signi-
ﬁcant difference in metabolites levels between people with
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Translational PsychiatryASD and TD in adulthood. The NAA levels in the parietal lobe
and cerebellum showed a trend for decreased measures in
adults with ASD compared with those with TD (P¼0.01 in the
parietal lobe and P¼0.004 in the cerebellum), although these
differences did not reach statistical signiﬁcance after the
Bonferroni correction was applied (Table 2).
In addition, it was conﬁrmed that Bonferroni corrections for
multiple comparisons were not too strict, because correction
using the Student–Newman–Kuels procedure did not change
the results both for childhood and adulthood.
Sensitivity analyses. All sensitivity analyses performed in
the speciﬁed-subgroups with more homogeneous quality
showed signiﬁcant reductions in NAA measures in the frontal
lobe of children with autism (Po0.05, Bonferroni-corrected).
These results demonstrated the robustness of reduced
frontal NAA level during childhood even after considering
methodological and participant’s heterogeneity such as
comorbidity of other neuropsychiatric diseases and intellec-
tual disability, medication status, diagnostic methods, ﬁeld
strength of MR scanner, types of MRS measures and
implementation of segmentation within VOI. In the other
areas, some sensitivity analyses revealed that the signiﬁcant
effect of low NAA level disappeared in some subgroups.
In the AHC, parietal cortex, temporal regions and thalamus,
the signiﬁcance of NAA reductions was preserved in the
most subgroups, such as ASD individuals with no comorbid
epilepsy, no medications and acquisition of MRS in a
1.5-tesla scanner (Supplementary Table 1).
Meta-regression. The current meta-regression revealed a
signiﬁcant inverse effect of mean age of participants on NAA
measures in the frontal lobe (P¼0.009), but in the AHC or
parietal cortex (Figure 3). Even after excluding heterogeneity
of participants and methodologies in the included study,
meta-regression analyses in speciﬁed subgroups further
demonstrated the signiﬁcant effects of mean age in the
frontal lobe. These analyses were performed in studies
with implementation of segmentation within VOIs (Po0.001),
with multi-voxel MRS (P¼0.021), with 1.5-tesla scanner
(P¼0.004), with participants without comorbid epilepsy
(P¼0.001), without medication (P¼0.006), without mental
retardation (P¼0.032) and without participants diagnosed
not using ADI-R or ADOS (P¼0.006).
The meta-regression revealed signiﬁcant effects of the type
of MRS measures and the employment of segmentation
within VOIs on the NAA levels in AHC (Po0.05). However, no
potential modiﬁers signiﬁcantly affect the NAA levels in the
frontal and parietal regions (Supplementary Table 2).
Between-study heterogeneity. No signiﬁcant heterogeneity
was detected in all the metabolites in any regions but in mI
measure in AHC and cerebellum during childhood (I
2¼78%
and 80%, respectively) (Table 2).
Publication bias. The linear regression test showed signi-
ﬁcant publication bias was not detected in most metabolites
(5/6) but in the parietal NAA of children (Po0.1; Table 2).
Discussion
To our knowledge, this is the ﬁrst systematic review and
meta-analysis of
1H-MRS studies in people with ASD. A total
of 22 studies were integrated in the meta-analyses, of which
1476
1H-MRS measures from 31 data sets at maximum, 844
measures from ASD and 632 measures from TD individuals.
The current meta-analysis demonstrated that NAA levels in
the frontal, parietal, temporal lobule, AHC and thalamus were
signiﬁcantlylowerinASD childrencomparedwithTDcontrols.
In contrast, no signiﬁcant difference in the any metabolite
levels was found in adulthood. Importantly, our meta-regres-
sion analysis provides the ﬁrst evidence that the degree of
lower frontal NAA levels linearly declined with aging from
childhood to adulthood in ASD people. The systematic review
showed obvious methodological heterogeneities across
studies, including in comorbid epilepsy, psychotropic medica-
tions, mental retardation, ﬁeld strength of MR scanners, types
ofMRSmeasures,utilization ofsegmentationwithin VOIsand
diagnostic tools. However, the sensitivity analyses further
emphasized the robustness of current ﬁndings, especially
regarding the lower-than-normal frontal NAA level in ASD
children, since the potential confounds, heterogeneity bet-
ween studies and publication bias did not signiﬁcantly affect
the ﬁndings.
The ﬁnding of robustly lower-than-normal frontal NAA
during childhood seems to be consistent with the importance
of this area in the pathophysiology of ASD indicated by
previous ﬁndings from several lines of research.
6,40–46
Previous functional imaging studies have repeatedly reported
dysfunctional prefrontal cortices during psychological tasks
requiring theory of mind,
47 social perception
48,49 and self-
referencing.
43 The presence of early brain enlargement
especially in frontal lobe
50 shown on structural MRI in autism
244 Potentially relevant citations identified
197 Citations excluded 
Excluded as participants criteria or 
methodology did not meet the 
inclusion criteria of the current review
47 Potentially appropriate articles identified for further screening
23 Citations excluded 
9 No original data or case report 
10 Not meet participants criteria
2 Not utilize 1H-MRS 
2 Not report new data
24 Articles included into the database
2 Citations excluded 
1 Not report raw data
1 Not report standard deviation
22 Articles included into the meta-analysis
Figure 1 Process of study selection.
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Translational Psychiatryis well established.
3–5 Previous post-mortem studies have
also shown several deviations in various histological tissues
including glial cells, von Economo neurons and neuronal
organization in frontal cortices of ASD.
6
The present linear regression analysis demonstrated a
strong inverse correlation between decrement of frontal NAA
and mean age in ASD subjects. Previous brain structural
ﬁndings revealed abnormal trajectory of brain growth, such
that the overall brain size in autism was slightly reduced at
birth, dramatically increased within the ﬁrst year of life, then
gradually plateaued in adulthood.
3–5 As the current meta-
analyses included studies involving participants with mean
ages between 4 and 35, the period of which the meta-
analyses covered corresponds to the phase of gradual
dissipation of early brain overgrowth in ASD. It is notable
that the decrease and subsequent recovery in NAA level
was found during the period showing a signiﬁcant increase
and subsequent normalization in brain size in ASD, because
these overlapping effects were inferred on the basis of
independent data.
The current neurochemical ﬁndings could provide some
insight into the histochemical background of the abnormal
trajectory of autistic brain growth. Although the histological
background is yet to be uncovered, several hypotheses
have been formulated.
6,7 These hypotheses could be divided
into two major categories. The ﬁrst is abnormalities asso-
ciated with neurons: for example, excessive numbers of
neuron, synapse, or minicolumns and excessive and/or
premature growth of axon, dendrite, or neuron cell bodies.
The second is abnormalities associated with glial cells, such
asexcessivenumbersofglia,activatedandenlargedglia,and
excessive and/or premature myelination. NAA is localized
mainly in the cell bodies, axons, dendrites and dendritic
spines of mature neurons, and is considered to function as a
marker of functional and structural neuronal integrity.
9
Although recent studies have suggested NAA expressed
Figure2 ForestplotoffrontalN-acetylaspartate(NAA).StandardizedmeandifferencesforNAAmeasuresinfrontallobebetweensubjectswithautismspectrumdisorders
(ASDs) and those with typical development (TD) in child and adulthood. The forest plot displays standardized mean differences and 95% conﬁdential intervals (CIs).
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Translational Psychiatryby oligodendrocytes,
51 NAA is less distributed in glia.
52
Therefore, since brain enlargement because of increase in
neuron number should heighten NAA level in autistic brain, it
is more likely that reduced NAA measures during childhood
reﬂect decreased neuron density induced by increasing brain
volume because of a factor other than associated with
neurons.
Considered together, among the two possible explanations
for early brain expansion in ASD, increased cell bodies,
axons, dendrites and dendritic spines of neurons seems less
likely than abnormalities associated with glia. Glial cells (for
example, astrocytes) have been shown to increase in volume
after birth.
53 As glial cells initially occupy large percentage of
brain volume,
54 increased glial cell volume may be a major
factor in brain enlargement without a signiﬁcant increase in
the NAA measure of
1H-MRS. Previous post-mortem studies
have reported glial abnormalities that can contribute the
abnormal volume increase, such as microglial and astroglial
activation and increased microglial density, in the prefrontal
cortex in ASD.
55,56 Thus, it is reasonable to hypothesize that
proliferation of glial cells diluting the density of neurons is a
major factor in the abnormal brain overgrowth and decreased
NAA levels observed in children with ASD.
The hypothesis that proliferation of glia could cause brain
expansion with decreased neuron density and low NAA is
consistentwithobservationsinsomeneurologicalandgenetic
diseases. Previous studies have demonstrated decreased
NAA because of abnormal synthesis of glia in patients with
glioma.
57Someotherdiseasesmanifestingmacrocephaly,for
example, neuroﬁbrosis type 1 demonstrates decreased NAA
measures. It was concluded that the reduced NAA measures
in neuroﬁbrosis type 1 was caused by increased brain volume
because of excess myelination.
58
Proliferation of glia can also explain the transient brain
expansion during the neonatal period and infancy, and is
consistent with the subsequent preservation of behavioral
dysfunction in the period of gradually normalizing for brain
expansion in ASD. Transient microglial cell proliferation and
subsequent irreversible dysfunction could occur after inﬂam-
mation or hypoperfusion.
59 Existence of inﬂammation or
hypoperfusion during neonatal and infancy in ASD has also
been suggested by several lines of evidence,
55,56 including
decreased serum levels of adhesion molecules and a
correlation with head circumference at birth.
60 Diminishing
of transiently increased glia after early infancy is consistent
with the normalization of transiently expanded brain size
and decreased NAA during the overlapped time period.
However, because we could not ﬁnd the MRS study involved
the participants with the age o1, abnormal brain growth
during this period is out of the ﬁnding of the current meta-
analysis.
Several methodological considerations and limitations of
ourstudyshouldbeconsidered.First,becauseofthenatureof
meta-analysis, we can make statistical analysis only at the
level of studies. There is no way to conﬁrm whether the
participants of included studies actually exhibited enlarged
brains during childhood. Second, although inverse effect
of age on frontal NAA was shown robustly by the meta-
regression analysis performed with the child–adult combined
group, it remains unclear whether NAA levels in adults with
ASD are equal to, or exceed, levels in TD, because of the
relatively small number of included studies in adulthood.
Third, because the most included studies utilized 1.5-tesla
instead of 3-tesla scanner, it might be insufﬁcient to collect
reliable data about several metabolites, which could not be
reliably evaluated with insufﬁcient strength of magnetic ﬁeld
suchasGlx.Fourth, theincluded studiesdisplay considerable
heterogeneity such as variations in the type of metabolite
measures and implementation of segmentation. The use of
a ratio to Cre is based on the hypothesis that there is no
difference in Cre levels between ASD and TD, which is shown
to be questionable in the current meta-analysis. Not imple-
menting segmentation is also based on the hypothesis the
same proportion of cerebrospinal ﬂuids in each VOI between
cases and controls, while structural differences between ASD
and TD have been repeatedly demonstrated. Furthermore,
the abnormalities in metabolites level of ASD were reported to
be different between those in gray matter and white matter.
30
We employed the random effect model and the sensitivity
analyses in more homogeneous subgroups to control the
heterogeneity, and the main ﬁndings were preserved when
the heterogeneity was controlled. However, the current
results were partially affected by such heterogeneity, and
should be interpreted carefully. Fifth, although we categorized
locations of VOIs into six brain areas with the similar
developmental origin,
24 the classiﬁcation might be criticized
to be over-simpliﬁed considering the functional variability
within each sub-areas.
In conclusion, the current meta-analysis robustly showed a
signiﬁcant frontal NAA reduction in ASD children compared
with TD, and further demonstrated a signiﬁcant linear
correlation between older age and a smaller magnitude of
NAA decrease. This NAA reduction then disappeared in
adulthood. Taken together with previous ﬁndings suggesting
early brain overgrowth and subsequent normalization during
the same time period, the current ﬁndings support the
hypothesis that abnormal brain enlargement in ASD is mainly
caused by increases of non-neuron tissues, such as glial
Figure 3 The relationship between effect sizes for reduced N-acetylaspartate
(NAA) and ages of study participants. Effect sizes from each comparison of
VOIs are plotted by the mean age of participants with autism spectrum disorders
of the study. The line of best ﬁt shows a gradual but substantial decrease in
NAA reduction. No data were obtained from individuals before the age of 4 years.
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Translational Psychiatrycell proliferation. The current systematic review and meta-
analysis emphasized the importance and implication for
future research. Future longitudinal and large-scale original
study with sufﬁcient statistical power that is free from the
methodological limitations is required to test the current
hypothesis.
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